Tanize Louize Milbradt

Tanize Louize Milbradt

Auto-generated profile, based on publicly available information

Tanize Louize Milbradt

Division of Medicine, Federal University of Santa Maria, Santa Maria, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
TMTanize Louize Milbradt
Tanize Louize Milbradt
RSRenan Yuji Ura Sudo
Renan Yuji Ura Sudo
MGMarília Oberto da Silva Gobbo
Marília Oberto da Silva Gobbo
SAStephen Akinfenwa
Stephen Akinfenwa
BMBrenda Moura
Brenda Moura

17 June 2025 in Current Eye Research
Verified
Journal Article
Closed access
MLMatheus Henrique Monteiro Leber
Matheus Henrique Monteiro Leber
TMTanize Louize Milbradt
Tanize Louize Milbradt
AFAlexandre Yamada Fujimura
Alexandre Yamada Fujimura
YSYasmin Picanco Silva
Yasmin Picanco Silva
Dillan Cunha AmaralDillan Cunha Amaral
Dillan Cunha Amaral
RBRubens Belfort
Rubens Belfort
Myopia is a significant public health concern with increased risk of ocular complications. Intense Foveal Red Light (IFRL) therapy has been explored in myopia control, but its efficacy at the pre-myopic stage remains underexplored. The use of this therapy in a population without a myopia diagnosis may offer a new window for the prophylactic application of IFRL therapy. The purpose of this meta-analysis is to determine the effectiveness of IFRL therapy in children with pre-myopia. PubMed, Embase, and the Cochrane Library were systematically searched for studies investigating the effects of IFRL therapy on myopia incidence, changes in axial length (AL), choroidal thickness (CT), and cycloplegic spherical equivalent refraction (SER). Two independent reviewers screened studies, extracted data, and assessed the risk of bias. Meta-analyses were conducted using random-effects models to estimate the pooled effect sizes. Of 365 studies identified, 4 met the criteria, totaling 619 participants (mean age 8.48 years, 51.8% female). At 6 months, IFRL significantly reduced myopia incidence (Risk Difference [RD] - 0.1; 95% CI -0.15 to -0.05; p < 0.01), with benefits persisting at 12 months (RD -0.17; 95% CI -0.26 to 0.09; p < 0.01). IFRL also reduced AL at 6 months (Mean Difference [MD] - 0.12 mm; 95% CI -0.16 to -0.09; p < 0.01) and 12 months (MD -0.18 mm; 95% CI -0.23 to -0.14; p < 0.01), increased CT (MD 22.34 µm; 95% CI 5.45-39.24; p < 0.01), and improved SER at 6 (MD 0.27 D; 95% CI 0.23 to 0.32; p < 0.01) and 12 months (MD 0.36 D; 95% CI 0.27-0.46; p < 0.01). IFRL effectively reduced myopia incidence, AL, and improved SER and CT. These findings support further research on its long-term efficacy and safety, particularly regarding potential adverse effects and durability of outcomes. Overall, IFRL may offer a preventive strategy for pre-myopic children.

19 September 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
LCL. F. Crosara
L. F. Crosara
POP. V. B. Orsini
P. V. B. Orsini
KEK. Eskandar
K. Eskandar
SKS. M. Khalil
S. M. Khalil
GCG. S. F. Castilhos
G. S. F. Castilhos
CPC. E. Philip
C. E. Philip

24 September 2026 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
IPIago Zang Pires
Iago Zang Pires
AFAlexandre Yamada Fujimura
Alexandre Yamada Fujimura
MGMarília Oberto da Silva Gobbo
Marília Oberto da Silva Gobbo
RSRenan Yuji Ura Sudo
Renan Yuji Ura Sudo
TMTanize Louize Milbradt
Tanize Louize Milbradt
GCGustavo Franco Carvalhal
Gustavo Franco Carvalhal